USSTOCK.TODAY
Market Closed
Log in Sign up

Amgen and AstraZeneca Announce Phase 3 Clinical Trial Results for Tezspire in Eosinophilic Esophagitis

Nasdaq +1 ·

AZN Astrazeneca plc
$168.45 -0.22%
View chart & analysis →
AMGN -0.14%
  1. 1Amgen and AstraZeneca announced the full results of the Phase 3 CROSSING trial for Tezspire to treat eosinophilic esophagitis (EoE).
  2. 2A 68.9% histological remission rate was recorded in patients receiving 420mg of Tezspire at week 24.
  3. 3Jay Bradner, Executive Vice President of AI and Data R&D at Amgen, said that patients with eosinophilic esophagitis need a new therapeutic approach.

So what's the key point?

Amgen and AstraZeneca released clinical trial results for an esophagitis treatment. The treatment showed effectiveness in 68.9% of patients and could serve as a new way to manage the condition.

Source Nasdaq +1 · View original ↗

Related 3-line summaries

Johnson & Johnson and Amgen as Dividend Stock Investment Options The Motley Fool +1 · 20h agoArcus Biosciences shares fall after clinical data release; Salesforce pursues Braze acquisition Investing.com +3 · yesterdayAstraZeneca to Partner with Oracle to Improve AI-Driven Clinical Trials and Patient Care The Wall Street Journal +3 · yesterday
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news